STAAR SURGICAL COSTAAEarnings & Financial Report
STAAR Surgical Co is a global ophthalmic medical device firm. It designs, makes and sells implantable collamer lenses (ICLs) for minimally invasive vision correction, plus supporting surgical products for ophthalmologists across North America, Europe, Asia Pacific and other key regional markets.
STAA Q4 FY2024 Key Financial Metrics
Revenue
$49.0M
Gross Profit
$31.6M
Operating Profit
$-27.9M
Net Profit
$-34.2M
Gross Margin
64.7%
Operating Margin
-57.0%
Net Margin
-69.9%
YoY Growth
-35.8%
EPS
$-0.69
STAAR SURGICAL CO Q4 FY2024 Financial Summary
STAAR SURGICAL CO reported revenue of $49.0M (down 35.8% YoY) for Q4 FY2024, with a net profit of $-34.2M (down 541.3% YoY) (-69.9% margin). Cost of goods sold was $17.3M, operating expenses totaled $59.6M.
Key Financial Metrics
| Total Revenue | $49.0M |
|---|---|
| Net Profit | $-34.2M |
| Gross Margin | 64.7% |
| Operating Margin | -57.0% |
| Report Period | Q4 FY2024 |
STAAR SURGICAL CO Annual Revenue by Year
STAAR SURGICAL CO annual revenue history includes year-by-year totals (for example, 2024 revenue was $313.9M).
STAAR SURGICAL CO Quarterly Revenue & Net Profit History
STAAR SURGICAL CO results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $49.0M | -35.8% | $-34.2M | -69.9% |
| Q3 FY2024 | $88.6M | +10.3% | $10.0M | 11.3% |
| Q2 FY2024 | $99.0M | +7.3% | $7.4M | 7.5% |
| Q1 FY2024 | $77.4M | +5.2% | $-3.3M | -4.3% |
| Q4 FY2023 | $76.3M | +299.4% | $7.8M | 10.2% |
| Q3 FY2023 | $80.3M | +5.6% | $4.8M | 6.0% |
| Q2 FY2023 | $92.3M | +13.8% | $6.1M | 6.6% |
| Q1 FY2023 | $73.5M | +16.3% | $2.7M | 3.7% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.5M | $92.3M | $80.3M | $76.3M | $77.4M | $99.0M | $88.6M | $49.0M |
| YoY Growth | 16.3% | 13.8% | 5.6% | 299.4% | 5.2% | 7.3% | 10.3% | -35.8% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $418.9M | $440.7M | $471.5M | $488.7M | $492.5M | $512.7M | $537.6M | $509.5M |
| Liabilities | $80.0M | $87.0M | $92.9M | $102.7M | $99.7M | $103.6M | $109.5M | $112.2M |
| Equity | $342.8M | $357.6M | $378.6M | $386.0M | $392.8M | $409.1M | $428.1M | $397.3M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.1M | $-6.3M | $-6.0M | $32.0M | $21.7M | $-10.4M | $3.8M | $642000 |